As of April 11, 2026, Roche’s Herceptin (Trastuzumab) remains a cornerstone in the global fight against HER2-positive breast and gastric cancers. This breakthrough monoclonal antibody has transformed the prognosis for patients, offering a targeted approach that specifically blocks the HER2 protein, which fuels the growth of certain aggressive tumors.

At Onco Medicine, we are committed to providing the latest pharmaceutical insights and ensuring access to these life-saving treatments. The 2026 clinical landscape continues to prioritize standardized dosing and professional administration for optimal patient outcomes.

Understanding Dosage Variations and Clinical Roles

Herceptin is available in several dosage strengths to accommodate different clinical protocols and patient needs. The choice of dosage depends on the specific cancer type, stage, and whether the drug is being used in a neo-adjuvant or adjuvant setting.

• Herceptin (Herclon) 150mg Injection: Often used as part of a loading dose strategy or in combination therapies. This professional pharma form ensures precise administration for localized treatment.
• Herceptin (Herclon) 440mg Injection: The most widely used strength for maintenance therapy, offering a balanced concentration for long-term clinical management.
• Herceptin 660mg Injection: A higher concentration variant designed for intensive protocols, requiring careful monitoring by oncology professionals.

2026 Pricing and Availability

In our effort to maintain transparency and support patient financial navigation, we provide the current market pricing for these essential treatments:

The Trastuzumab Mechanism of Action

Trastuzumab works by binding to the Extracellular Domain IV of the HER2 protein. This action performs several critical functions:

• Inhibition of Signal Transduction: Prevents the activation of cellular pathways that promote tumor proliferation.
• Antibody-Dependent Cellular Cytotoxicity (ADCC): Recruits the body's natural killer (NK) cells to directly attack the tumor.
• Prevention of HER2 Extracellular Domain Shedding: Keeps the receptor intact for better immune recognition.
• Inhibition of HER2 Extracellular Domain Shedding: Prevents the release of the HER2 ECD, which is associated with decreased therapeutic efficacy.

Science-driven recovery is built on precision and access. Herceptin continues to set the standard for HER2-targeted therapy, and Onco Medicine is proud to be your trusted global supplier. Consult your oncologist to determine the optimal dosage and schedule for your specific journey.